1. Home
  2. RFL vs CUE Comparison

RFL vs CUE Comparison

Compare RFL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.23

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.56

Market Cap

49.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFL
CUE
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.4M
49.6M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
RFL
CUE
Price
$1.23
$0.56
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.00
AVG Volume (30 Days)
96.8K
375.9K
Earning Date
11-19-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$917,000.00
$7,100,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.96
N/A
52 Week Low
$1.17
$0.54
52 Week High
$3.19
$1.75

Technical Indicators

Market Signals
Indicator
RFL
CUE
Relative Strength Index (RSI) 40.80 34.94
Support Level $1.20 $0.55
Resistance Level $1.29 $0.66
Average True Range (ATR) 0.07 0.05
MACD 0.00 -0.00
Stochastic Oscillator 41.67 10.75

Price Performance

Historical Comparison
RFL
CUE

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: